JP Morgan Chase
SMMT icon

JP Morgan Chase’s Summit Therapeutics SMMT Stock Holding History

JP Morgan Chase’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,200
Closed -$161K – 7859
2025
Q4 		$161K Hold
9,200
– – ﹤0.01% 5639
2025
Q3 		$190K Buy
+9,200
New +$223K ﹤0.01% 5547

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase's SMMT Position: Q1 2026 in Review

JP Morgan Chase reduced its Summit Therapeutics (SMMT) stake by 4.3% in Q1 2026, selling an estimated $46.4K and leaving 64,554 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #4554.

JP Morgan Chase first reported a position in SMMT in Q4 2017 and has held it in 26 quarters since. The position peaked at $11.1M in Q1 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • JP Morgan Chase held 64,554 shares of Summit Therapeutics worth $1.1M as of Q1 2026.
  • JP Morgan Chase sold 2,868 Summit Therapeutics shares in Q1 2026, an estimated $46.4K.
  • Summit Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4554 holding.
  • JP Morgan Chase first reported a position in Summit Therapeutics in Q4 2017 and has held it in 26 quarters since.
  • JP Morgan Chase's Summit Therapeutics position peaked at $11.1M in Q1 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.